Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Marketing Remicade Aiming at 20,000 of 110,000 MTX Users: Tanabe Seiyaku
November 21, 2005
- So Far So Good: Dr Takenaka of Astellas
November 21, 2005
- Shionogi: Sales Up Just 1.6%; Crestor Boosts Profits
November 21, 2005
- Profits and CSR "Not Mutually Exclusive": Mr Mallet of Pfizer
November 21, 2005
- MCHD: MCC, MPC Post Growth in Sales and Profits
November 21, 2005
- Pfizer Health Research Forum
November 21, 2005
- Dainippon Sumitomo Enjoying "Smooth Start": Mr Miyatake
November 21, 2005
- R&D NEWS IN BRIEF
November 21, 2005
- Costs of Domestic Clinical Trials Remain Excessive: Mr Nakajima of JPMA
November 21, 2005
- FPMAJ, JPMA Petition on FY2006 Budget, Taxation System
November 21, 2005
- Drug Benefits Discussed by EAD Director Futagawa
November 21, 2005
- JMA Objects that GPs Income Is Not as High as Reported by Korosho
November 21, 2005
- Medical Fees Must Be Reduced by at Least 3%: MOF Council
November 21, 2005
- FPMAJ's Mr Mukaida Criticizes Korosho's Reform Proposals
November 21, 2005
- Are Medical Professionals' Incomes Acceptable?
November 14, 2005
- Eiken Chemical to Build Production Base in China
November 14, 2005
- REGULATORY NEWS IN BRIEF
November 14, 2005
- Korosho Proposes Discussion Topics for Reform of Med. Materials Pricing
November 14, 2005
- Mid-2006 Submission Envisioned for Parkinson's Disease Treatment: Kyowa Hakko
November 14, 2005
- NBI, Pfizer Japan: Survey Finds Little Awareness of COPD
November 14, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…